Filing Analysis
Voyager Therapeutics announced its second quarter 2026 financial results and provided corporate updates. The filing serves as a formal announcement of quarterly earnings performance.
📋 Key Facts
- Company reported Q2 2026 financial and operating results on August 6, 2026.
- The report includes an official press release (Exhibit 99.1) detailing the company's financial condition.
Voyager Therapeutics presented positive GLP toxicology data for its Alzheimer's disease candidate, VY1706, at the Alzheimer’s Association International Conference. The data demonstrated favorable tolerability and significant tau protein reduction in non-human primates.
🚩 Red Flags
- Standard cautionary language regarding the sufficiency of cash resources to fund operations (typical for biotech micro-caps).
📋 Key Facts
- Presented 3-month and 6-month GLP toxicology data for VY1706 (tau silencing gene therapy) at the Alzheimer's Association International Conference on July 13, 2026.
- Data showed favorable tolerability in non-human primates (NHPs) with no adverse findings in CNS, dorsal root ganglia, or peripheral organs up to a dose of 5 x 10^13 vg/kg.
- Single intravenous dose achieved up to 75% reduction in MAPT mRNA and tau protein in key brain regions through six months.
- ALPL receptor was identified as the mediator for blood-brain barrier transport, supporting cross-species translatability.
- FDA IND clearance was received in June 2026; multi-site, open-label, dose-escalation clinical trials are planned for the second half of 2026.
Voyager Therapeutics held its 2026 Annual Meeting of Stockholders on June 9, 2026, where shareholders approved a significant increase in the number of authorized shares of common stock. The company also elected Class II directors and ratified its independent auditor.
🚩 Red Flags
- Significant increase in authorized shares (doubling the common stock from 120M to 240M) often precedes dilutive equity offerings to raise capital.
📋 Key Facts
- Authorized shares of capital stock increased from 125,000,000 to 245,000,000.
- Authorized shares of common stock increased from 120,000,000 to 240,000,000.
- The Certificate of Amendment was filed with the Delaware Secretary of State on June 9, 2026.
- Stockholders elected James A. Geraghty, Steven Hyman, M.D., and Alfred Sandrock, M.D., Ph.D. as Class II directors.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
Voyager Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for VY1706, a tau silencing gene therapy for Alzheimer's disease. The company intends to begin a multi-site, open-label, dose-escalation clinical trial in the second half of 2026.
📋 Key Facts
- FDA cleared the IND application for VY1706 on June 1, 2026.
- VY1706 targets both intracellular and extracellular tau for Alzheimer's disease (AD).
- Clinical trial dosing is expected to commence in the second half of 2026.
- The study will enroll up to 18 adult participants with early AD and confirmed tau pathology via PET imaging.
- Primary endpoint is safety and tolerability; secondary endpoints include CSF biomarkers and tau PET imaging changes.
- Maximum dose will not exceed 5 x 10^13 vector genomes per kilogram.
Voyager Therapeutics announced its first quarter 2026 financial results and provided general corporate updates. The announcement was made via a press release furnished as Exhibit 99.1.
📋 Key Facts
- Announcement of Q1 2026 financial results on May 7, 2026.
- Corporate updates provided in conjunction with financial results.
- Filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
- The report was signed by CEO Alfred Sandrock, M.D., Ph.D.
Voyager Therapeutics announced the resignation of CFO Nathan Jorgensen, Ph.D., effective May 8, 2026. The company has appointed current COO Robin Swartz as Principal Financial Officer and VP of Finance Amy Quinlan as Principal Accounting Officer to assume his responsibilities.
📋 Key Facts
- Nathan Jorgensen, Ph.D. resigned as CFO on April 15, 2026, effective May 8, 2026, to pursue a new opportunity.
- Robin Swartz, age 55, currently the COO and Chief Business Officer, will become the Principal Financial Officer and Treasurer.
- Amy Quinlan, age 51, currently VP of Finance, will become the Principal Accounting Officer.
- The company stated there were no disagreements with Dr. Jorgensen regarding operations, policies, or practices.
- Robin Swartz has over 10 years of finance experience at Sanofi Genzyme prior to joining Voyager.
Voyager Therapeutics reported its fourth quarter and full year 2025 financial results and provided corporate updates on March 9, 2026.
📋 Key Facts
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The report covers the fiscal period ending December 31, 2025.
- A press release detailing the financial and operating results was furnished as Exhibit 99.1.
- The report was signed by CEO Alfred Sandrock, M.D., Ph.D.
Voyager Therapeutics announced the resignation of its Chief Medical Officer, Toby Ferguson, M.D., Ph.D., effective February 20, 2026. CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will assume Dr. Ferguson's clinical development responsibilities on an interim basis.
🚩 Red Flags
- Departure of a key executive (CMO) in a biotech company can disrupt clinical program momentum.
- Interim leadership structure for critical medical/clinical functions may indicate a transition gap.
📋 Key Facts
- Toby Ferguson, M.D., Ph.D. is resigning as Chief Medical Officer effective February 20, 2026.
- The resignation is to pursue a new opportunity and is not due to any disagreement with the Company.
- CEO Alfred W. Sandrock, Jr., M.D., Ph.D. will assume key clinical development responsibilities on an interim basis.
Voyager Therapeutics has filed an 8-K to provide updates to the investment community via a corporate investor presentation and a letter to stockholders. The filing is primarily for Regulation FD compliance and does not contain new material financial developments.
🚩 Red Flags
- Forward-looking statements mention risks regarding the 'sufficiency of the Company's cash resources,' which is a common caution in biotech but requires monitoring for liquidity.
📋 Key Facts
- The company distributed a corporate investor presentation (Exhibit 99.1) and a letter to stockholders (Exhibit 99.2).
- Information provided under Item 7.01 is intended for investor relations purposes and is not deemed 'filed' for liability purposes under Section 18 of the Exchange Act.
- The filing includes standard cautionary language regarding forward-looking statements related to clinical milestones, regulatory submissions, and cash sufficiency.
Voyager Therapeutics announced its third quarter 2025 financial results and corporate updates on November 10, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Announcement date: November 10, 2025
- Reporting period: Third Quarter 2025
- The company furnished a press release (Exhibit 99.1) containing the full financial and operating results.
Voyager Therapeutics announced its intention to present at the Citi 2025 Biopharma Back to School Conference on September 2, 2025. The company provided a presentation as Exhibit 99.1 to satisfy Regulation FD disclosure requirements.
📋 Key Facts
- Company is presenting at Citi’s 2025 Biopharma Back to School Conference.
- Presentation date: September 2, 2025, at 4:00 p.m. ET.
- The filing includes Exhibit 99.1 containing the presentation materials.
Voyager Therapeutics announced its second quarter 2025 financial results and corporate updates on August 6, 2025. The filing serves as a formal notice of the earnings release via Exhibit 99.1.
📋 Key Facts
- Reporting date: August 6, 2025
- Period covered: Second Quarter 2025
- Company announced financial results and corporate updates via press release (Exhibit 99.1).
Voyager Therapeutics reported the results of its 2025 Annual Meeting of Stockholders held on June 3, 2025. The meeting included the election of Class I directors, ratification of Ernst & Young LLP as independent auditors, and approval of new stock incentive plans.
📋 Key Facts
- Stockholders elected Grace E. Colón, Catherine J. Mackey, Glenn Pierce, and George Scangos to serve as Class I directors until 2028.
- The 2025 Stock Incentive Plan was approved by stockholders.
- The Amended and Restated 2015 Employee Stock Purchase Plan was approved by stockholders.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2025.
- A non-binding advisory proposal regarding executive compensation (Say-on-Pay) was approved.
Voyager Therapeutics announced its first quarter 2025 financial and operating results via a press release. This is a routine quarterly earnings update.
📋 Key Facts
- Reported date of event: May 6, 2025
- Announcement covers Q1 2025 financial and operating results
- The information was furnished under Item 2.02 and is not considered 'filed' for liability purposes under Section 18.
Voyager Therapeutics announced its fourth quarter and full year 2024 financial results and provided corporate updates on March 11, 2025.
📋 Key Facts
- Reported date: March 11, 2025
- Reporting period: Fourth Quarter and Full Year 2024
- The filing includes a press release (Exhibit 99.1) containing financial and operating results.
- Information under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
Voyager Therapeutics announced a strategic pivot for its SOD1 ALS Program (VY9323), deciding to assess alternate payloads after non-human primate data suggested the current payload would not meet the desired product profile. This decision results in the cancellation of planned mid-2025 IND/CTA filings for this specific candidate.
🚩 Red Flags
- Failure of lead development candidate (VY9323) to meet desired product profile in NHP studies.
- Delay/Cancellation of clinical milestone (IND filing) originally slated for mid-2025.
- Cash runway estimates are contingent on uncertain collaboration reimbursements from Neurocrine and Novartis.
📋 Key Facts
- SOD1 ALS Program (VY9323) will shift to assessing alternate payloads due to unfavorable 3-month NHP data regarding product profile.
- The decision does not impact the novel capsid component of VY9323.
- Mid-2025 IND/CTA filings for VY9323 are no longer anticipated.
- Company expects IND filings in 2025 from Neurocrine Biosciences for GBA1 and Friedreich’s ataxia programs.
- Company expects an IND filing in 2026 for VY1706 (tau silencing program).
- Estimated cash runway extends into mid-2027 based on current operating plans and collaboration reimbursements.
Voyager Therapeutics announced its third quarter 2024 financial and operating results via a press release. The filing is a standard earnings update under Item 2.02.
📋 Key Facts
- Company reported Q3 2024 financial and operating results on November 12, 2024.
- The announcement includes corporate updates alongside the financial results.
- Results are furnished in Exhibit 99.1 as a press release.
Voyager Therapeutics entered into an amendment to its existing Option and License Agreement with Novartis Pharma AG. The amendment grants Novartis an additional license for a capsid discovered via Voyager's TRACER platform, involving significant upfront and milestone payments.
🚩 Red Flags
- Prior rights for Novartis to exercise options on initial and additional targets (other than those already exercised) have expired as of the Amendment Effective Date.
📋 Key Facts
- Amendment effective date: September 3, 2024.
- Novartis to pay a one-time fee of $15 million.
- Voyager is eligible for up to $130 million in development, regulatory, and commercialization milestones for the first Licensed Product.
- Potential sales milestones of up to $175 million per Licensed Product.
- Royalty payments in the mid- to high-single-digit percentages of annual net sales.
Voyager Therapeutics announced its second quarter 2024 financial results and provided corporate updates via a press release. The filing serves as the formal mechanism to furnish these quarterly earnings results to the SEC.
📋 Key Facts
- Reported date: August 6, 2024
- Reporting period: Second Quarter 2024
- The company furnished a press release (Exhibit 99.1) containing financial and operating results.
Voyager Therapeutics announced the appointment of Nathan Jorgensen, Ph.D., M.B.A. as the new Chief Financial Officer, effective no later than July 8, 2024. Dr. Jorgensen brings significant biotechnology and investment experience to the role.
📋 Key Facts
- Nathan Jorgensen appointed as CFO, Principal Financial Officer, and Principal Accounting Officer.
- Commencement date set for no later than July 8, 2024.
- Annual base salary of $480,000 with a target cash bonus of 40%.
- Equity compensation includes 200,000 stock options (4-year vest) and 80,000 RSUs (3-year vest).
- Previous experience includes CFO at Vor Biopharma Inc. and Healthcare Portfolio Senior Manager at Qatar Investment Authority.
Voyager Therapeutics held its Annual Meeting of Stockholders on June 5, 2024. The meeting resulted in the election of three Class III directors and the ratification of Ernst & Young LLP as the independent auditor.
📋 Key Facts
- Annual Meeting of Stockholders held on June 5, 2024.
- Elected Michael Higgins, Jude Onyia, Ph.D., and Nancy Vitale to Class III director positions until the 2027 Annual Meeting.
- Approved a non-binding advisory proposal (Say-on-Pay) regarding executive compensation with significant majority support (35,949,375 'For').
- Ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
Voyager Therapeutics announced the commencement of dosing for its Phase 1a single ascending dose (SAD) trial of VY-TAU01. The study aims to evaluate the safety and pharmacokinetics of this anti-tau antibody in healthy volunteers for the treatment of Alzheimer’s disease.
📋 Key Facts
- First participants were dosed on May 16, 2024.
- The trial is a Phase 1a single ascending dose (SAD) study of VY-TAU01.
- Target indication: Alzheimer’s disease (inhibiting pathological tau spread).
- Study design: Randomized, double-blind, placebo-controlled.
- Expected enrollment: Approximately 48 patients in multiple cohorts.
- Location: Single site in the United States.
Voyager Therapeutics announced its first quarter 2024 financial and operating results via a press release. The filing is a standard quarterly earnings update.
📋 Key Facts
- Report date: May 13, 2024
- Reporting period: First Quarter 2024
- The company furnished Exhibit 99.1 containing the full press release regarding financial and operating results.
Voyager Therapeutics announced the resignation of CFO Peter P. Pfreundschuh, effective April 12, 2024, with a transition plan involving an interim principal financial officer and subsequent consulting services.
🚩 Red Flags
- Sudden departure of a key C-suite executive (CFO) can sometimes signal internal friction or disagreements over financial reporting, though no restatement was noted here.
- The use of a 'Transition Period' and subsequent consulting agreement indicates a managed exit rather than an immediate replacement.
📋 Key Facts
- CFO Peter P. Pfreundschuh resigned from all officer/director positions effective April 12, 2024 (Transition Date).
- Robin Swartz appointed as Principal Financial Officer and Principal Accounting Officer effective March 27, 2024.
- Pfreundschuh will serve as Senior Financial Advisor during a 'Transition Period' until May 5, 2024.
- Separation package includes 12 months of salary continuation and a prorated 2024 bonus.
- A consulting agreement is planned to run from the Separation Date through June 28, 2024 (with potential extension to July 31, 2024).
- Unvested RSUs and stock options will continue to vest during the Consulting Period subject to specific conditions.
Voyager Therapeutics announced the appointment of Toby Ferguson, M.D., Ph.D. as Chief Medical Officer, effective March 25, 2024. Dr. Ferguson joins from Biogen Inc., where he held several senior medical leadership roles.
📋 Key Facts
- Appointment of Toby Ferguson, M.D., Ph.D. as Chief Medical Officer (CMO).
- Commencement date for the new role is March 25, 2024.
- Annual base salary set at $485,000 with a target cash bonus of 40%.
- Equity compensation includes 210,000 stock options (4-year vest) and 105,000 RSUs (3-year vest).
- Dr. Ferguson previously served as VP, Head of Neuromuscular Development Unit at Biogen Inc.
Voyager Therapeutics announced its fourth quarter and full year 2023 financial results and provided corporate updates. The filing is a standard earnings release announcement.
📋 Key Facts
- Reported Q4 and Full Year 2023 financial and operating results on February 28, 2024.
- The filing includes Exhibit 99.1 containing the full press release.
- Information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Voyager Therapeutics announced a significant public offering of common stock and pre-funded warrants to raise approximately $93.5 million, alongside the closing of a $20 million private placement with Novartis. The company expects these combined inflows to extend its cash runway into 2027.
🚩 Red Flags
- Significant dilution: The issuance of over 11 million new shares (including warrants) represents substantial equity dilution for existing shareholders.
📋 Key Facts
- Public offering of 7,777,778 shares of common stock at $9.00 per share.
- Sale of pre-funded warrants for up to 3,333,333 shares at $8.999 per share.
- Estimated net proceeds from the offering: ~$93.5 million (up to ~$107.6 million with over-allotment).
- Closed a private placement of 2,145,002 shares to Novartis at $9.324 per share for ~$20.0 million on Jan 3, 2024.
- Anticipates an additional $80.0 million upfront payment from Novartis related to a Collaboration Agreement.
- Management estimates the combined cash inflows will fund operations into 2027.
Voyager Therapeutics entered into a significant License and Collaboration Agreement with Novartis Pharma AG involving AAV capsid technology for SMA and Huntington's disease programs. The deal includes substantial upfront cash, equity issuance, and massive potential milestone/royalty payments.
🚩 Red Flags
- Exclusivity clauses restrict Voyager from developing competing capsid therapies for the same targets (SMA and HD).
- Novartis has the right to terminate the Collaboration Agreement for any reason with 90 days' notice.
- Potential reduction in milestone/royalty payments if Novartis terminates due to a material breach by Voyager.
📋 Key Facts
- Novartis to pay $80 million upfront in cash.
- Novartis to purchase 2,145,002 shares of Voyager common stock for ~$20 million at $9.324 per share.
- Potential milestone payments: up to $200M (SMA Program) and $225M (HD Program).
- Potential sales milestones: up to $400M (SMA Program) and $375M (HD Program).
- Royalties in high single-digit to low double-digit percentages of annual net sales.
- Novartis gains exclusive rights for SMA program products and HD program products after IND filing/development stages.
- Includes standstill and lock-up restrictions via an Investor Agreement.